Azithromycin bronchitis treatment
Infectious inflammatory diseases of the respiratory tract are prominent in the structure of infectious pathology. Thereby, issues in choosing an appropriate antibacterial agent for the treatment of lower respiratory tract infections remains urgent.
Choosing a drug for antibacterial therapy should be based on its spectrum of action, the presumed causative agent susceptible to an antibiotic, and the pharmacokinetic properties of the antibacterial agent, antibiotic safety data, the drug characteristics form, dose administration and regimen. This allows for higher compliance in therapy and improves the pharmacoeconomic aspects of treatment.
Zithromax (azithromycin) is a medication that is often prescribed for the treatment of bronchitis. This is due to its high concentration in the bronchi after a relatively short time period following drug admission and a long elimination of short half-life, which makes antibiotic therapy short-lived. Positive feedback regarding this drug is largely due to its lack of post-antibiotic effect in adults. For example, it does not have a negative effect on intestinal microflora.
Within 10 years, the effectiveness of Zithromax in treating lower respiratory tract infections was studied in 29 large randomized controlled trials of 5,901 patients, including 762 children.
The effectiveness of both a 3- and a 5-day course of Azithromycin was high and was comparable to a 10-day course of treatment with reference drugs in most studies.
In 5 studies, azithromycin was superior in effectiveness to its competitors (co-amoxiclav, erythromycin, benzylpenicillin, and ceftibuten). The tolerability of therapy in the experimental and control groups was comparable. However, in 4 studies, Azithromycin caused undesirable effects less often than co-amoxiclav or cefuroxime axetil.
This difference was primarily due to a lower incidence of gastrointestinal disorders in the treatment using Zithromax.